G
GLP1 Lawsuit
Mass Tort Case Review
Call
GLP-1 Drug Injury

Ozempic Vision Loss & NAION Lawsuit

A 2024 Harvard/Mass Eye and Ear study found semaglutide users had a substantially elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION) — a sudden, often permanent vision loss. Lawsuits are now being filed.

Call (717) 724-7503

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.

What is NAION?

NAION is a sudden interruption of blood flow to the optic nerve. The classic presentation is painless, sudden loss of vision in one eye, often noticed on waking. There is no effective treatment, and most patients do not recover their vision.

The semaglutide link

Researchers at Harvard's Mass Eye and Ear published findings in JAMA Ophthalmology in mid-2024 showing dramatically elevated NAION risk in semaglutide users. The FDA is investigating; lawsuits allege the warning should be on the label now.

Do you qualify?

You may qualify if you experienced sudden, painless vision loss diagnosed as NAION while taking or shortly after taking Ozempic, Wegovy, or Rybelsus, and had no prior history of NAION in the affected eye.

Frequently Asked Questions

Get your free, confidential case review

Takes under 60 seconds. No fee unless you win.

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.